Amdocs Ltd 6-K, filed May 8, 2025
Amdocs Ltd (DOX)
About this 6-K
Amdocs Ltd filed this 6-K on May 8, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2025
Commission File Number 1-14840
AMDOCS LIMITED
Hirzel House, Smith Street,
St. Peter Port, Island of Guernsey, GY1 2NG
Amdocs, Inc.
625 Maryville Centre Drive, Suite 200, Saint Louis, Missouri 63141
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM 20-F ☒ FORM 40-F ☐
On May 7, 2025 Amdocs Limited (“Amdocs”) issued a press release announcing financial results for the quarter ended March 31, 2025. A copy of the press release and the accompanying presentation are furnished as Exhibits 99.1 and 99.2 to this Report of Foreign Private Issuer on Form 6-K.
The information in this Form 6-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.
EXHIBIT INDEX
| EXHIBIT |
DESCRIPTION | |
| 99.1 | Amdocs Limited Press Release Announcing Q2 Earnings, dated May 7, 2025 | |
| 99.2 | Fiscal Q2 2025 Earnings Presentation | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AMDOCS LIMITED | ||
| By: | /s/ Matthew E. Smith | |
| Matthew E. Smith | ||
| Secretary and Authorized Signatory | ||
Date: May 7, 2025
Exhibit 99.1
Amdocs Limited Reports Second Quarter Fiscal 2025 Results
Revenue of $1.13 Billion, down 9.4% YoY as Reported and up 4.0% YoY in Pro Forma(1) Constant Currency(2)
12-Month Backlog of $4.17 Billion, up 3.5% YoY on a Pro Forma(1) Basis
Expects Fiscal 2025 Revenue Outlook of (10.9)%-(9.1)% YoY as Reported
Reiterates Midpoint of Fiscal 2025 Revenue Growth Outlook in Pro Forma(1) Constant Currency(2)
Reiterates Fiscal 2025 Target for Double-Digit Total Shareholder Returns(3)
$1 Billion Share Repurchase Program Authorized
Second Quarter Fiscal 2025 Highlights
(All comparisons are against the prior year)
| • | Revenue of $1,128 million, down 9.4% as reported due to the phase out of certain business activities, and up 4.0% in pro forma(1) constant currency(2); revenue was above the midpoint of the $1,105-$1,145 million guidance range, despite a negative impact from foreign currency movements of approximately $2 million compared to our guidance assumptions |
| • | Record managed services revenue of $747 million, equivalent to approximately 66% of total revenue and up 3.7% as compared to last year’s second quarter |
| • | GAAP diluted EPS of $1.45, above the guidance range of $1.30-$1.38, primarily due to a lower than anticipated GAAP effective tax rate |
| • | Non-GAAP diluted EPS of $1.78 above the guidance range of $1.67-$1.73, primarily due to a lower than anticipated non-GAAP effective tax rate |
| • | GAAP operating income of $198 million; GAAP operating margin of 17.5%, up 500 basis points as compared to last year’s second fiscal quarter, reflecting the phase out of certain non-core business activities, restructuring charges recorded in last year’s second quarter, and a continued focus on operational excellence; GAAP operating margin was down 40 basis points sequentially |
| (1) | For comparison purposes, pro forma adjusts second quarter fiscal year 2024 revenue by approximately $150 million and fiscal 2024 revenue by approximately $600 million to reflect the end of certain low margin, non-core business activities; these activities substantially already ceased in the first quarter fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook |
| (2) | Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period |
| (3) | Expected total shareholder return assumes midpoint of fiscal year 2025 non-GAAP EPS growth outlook, plus dividend yield |
| (4) | Please refer to the Selected Financial Metrics tables below (figures may not sum because of rounding) |
| • | Non-GAAP operating income of $240 million; non-GAAP operating margin of 21.3%, up 290 basis points as compared to last year’s second fiscal quarter, reflecting the phase out of certain non-core business activities and a continued focus on operational excellence, and up 10 basis points sequentially |
| • | Free cash flow of $156 million, comprised of cash flow from operations of $172 million, less $16 million in net capital expenditures(4), including $25 million of restructuring payments; reiterates full year fiscal 2025 free cash outlook of $710 million to $730 million, excluding restructuring payments |
| • | Repurchased $135 million of ordinary shares during the second fiscal quarter |
| • | Twelve-month backlog of $4.17 billion, up approximately $30 million sequentially; adjusting for the phase out of certain business activities, twelve-month backlog was up 3.5%(1) as compared to last year’s second fiscal quarter |
JERSEY CITY, NJ – May 7, 2025 – Amdocs Limited (NASDAQ: DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended March 31, 2025.
“Q2 was a good quarter for Amdocs as we executed our strategy to deliver the cloud, digital, and AI-based solutions our customers need to ensure amazing experiences and seamless connectivity for billions of people each day. Revenue of $1.13 billion was up 4% from a year ago in pro forma(1) constant currency(2), and deal conversion was strong, led by continued sales momentum in cloud. Amdocs has won a deal to facilitate the migration of both Amdocs and non-Amdocs applications to Microsoft Azure for a Tier-1 European service provider, and we were also selected for the next phase of PLDT’s cloud modernization journey in Philippines. Consumer Cellular, a new US client for Amdocs, has chosen our SaaS-based connectX solution to expedite the launch of new digital brands. We also extended our collaboration with NVIDIA and other GenAI partners to further evolve Amdocs’ amAIz platform and to support the data and GenAI requirements of our customers,” said Shuky Sheffer, president and chief executive officer of Amdocs Management Limited.
“Amdocs achieved many project milestones this quarter, including successful production go-lives for NTT InfraNet in Japan, PLDT in Philippines, and A1 Bulgaria. Profitability improved sequentially, enabled by ongoing adoption of automation, AI, and other sophisticated tools, and free cash flow generation was strong, supported by healthy customer cash collections during the quarter. Q2 was also a record for managed services revenue, which is roughly 66% of total revenue. During the quarter, Amdocs expanded managed services activities with several customers under new multi-year agreements, maintaining the high renewal rates that support the company’s business visibility and recurring revenue base over time,” said Tamar Rapaport-Dagim, chief financial officer & chief operating officer of Amdocs Management Limited.
Sheffer concluded, “The level of global macroeconomic uncertainty has clearly risen in recent months, but we believe Amdocs is relatively well positioned to navigate the present environment due to our unique business model. We currently see a rich and encouraging deal pipeline which we are actively working to convert by utilizing our technology, project delivery and operations expertise. That said, we are closely monitoring for indirect impacts of macro conditions on our customers’ spending behavior. Overall, we are today reiterating the midpoint of our fiscal 2025 pro forma(1) revenue growth outlook in constant currency(2), which includes another year of double-digit growth in cloud. We are also reiterating our target of delivering double-digit expected total shareholder returns(3) for the fifth consecutive year, supported by significantly improved profitability and robust earnings to cash conversion.”
Revenue
(All comparisons are against the prior year period)
| In millions | ||||||||
| Three months ended | ||||||||
| March 31, 2025 | ||||||||
| Actual | Guidance | |||||||
| Revenue |
$ | 1,128 | $ | 1,105 - $1,145 | ||||
| Revenue Growth, as reported |
(9.4 | )% | ||||||
| Revenue Growth, Pro-forma (1) constant currency (2) |
4.0 | % | ||||||
| • | Revenue for the second fiscal quarter of 2025 was above the midpoint of Amdocs’ guidance, despite a negative impact from foreign currency movements of approximately $2 million relative to our guidance assumptions |
| • | Revenue for the second fiscal quarter includes a negative impact from foreign currency movements of approximately $11 million relative to the second quarter of fiscal 2024 and a negative impact from foreign currency movements of approximately $5 million relative to the first quarter of fiscal 2025 |
Net Income and Earnings Per Share
| In thousands, except per share data | ||||||||
| Three months ended | ||||||||
| March 31, | ||||||||
| 2025 | 2024 | |||||||
| GAAP Measures |
||||||||
| Net Income |
$ | 164,001 | $ | 119,425 | ||||
| Net Income attributable to Amdocs Limited |
$ | 163,243 | $ | 118,502 | ||||
| Diluted earnings per share |
$ | 1.45 | $ | 1.01 | ||||
| Non-GAAP Measures |
||||||||
| Non-GAAP Net Income |
$ | 201,017 | $ | 183,620 | ||||
| Non-GAAP Net Income attributable to Amdocs Limited |
$ | 200,259 | $ | 182,697 | ||||
| Non-GAAP Diluted earnings per share |
$ | 1.78 | $ | 1.56 | ||||
| • | Non-GAAP net income excludes amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition related liabilities measured at fair value, equity-based compensation expenses, restructuring charges, and other, net of related tax effects. For further details of the reconciliation of selected financial metrics from GAAP to Non-GAAP, please refer to the tables below. |
Capital Allocation
| • | Quarterly Cash Dividend Program: On May 7, 2025, the Board approved the Company’s next quarterly cash dividend payment of $0.527 per share, and set June 30, 2025 as the record date for determining the shareholders entitled to receive the dividend, which will be payable on July 25, 2025 |
| • | Share Repurchase Activity: Repurchased $135 million of ordinary shares during the second quarter of fiscal 2025. On May 7, 2025, the Board approved a new share repurchase plan authorizing the repurchase of up to $1 billion of ordinary shares at the Company’s discretion; this plan has no expiration date and is in addition to the current authorization, which, as of March 31, 2025, provided for up to $258 million of remaining repurchase authorization. Between the two authorizations, the Company has up to $1.26 billion of remaining repurchase authority |
Twelve-month Backlog
Twelve-month backlog was $4.17 billion at the end of the second quarter of fiscal 2025. On a pro forma(1) basis, adjusting the comparable period for the phase out of certain business activities, twelve-month backlog was up approximately 3.5% as compared to last year’s second fiscal quarter. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities.
Third Quarter Fiscal 2025 Outlook
| In millions, except per share data |
||||
| Q3 - 2025 | ||||
| Revenue |
$ | 1,110-$1,150 | ||
| GAAP Diluted earnings per share |
$ | 1.30-$1.38 | ||
| Non-GAAP Diluted earnings per share |
$ | 1.68-$1.74 | ||
| • | Third quarter revenue guidance assumes a positive $4 million sequential impact from foreign currency fluctuations as compared to the second quarter of fiscal 2025 |
| • | Third quarter non-GAAP diluted EPS guidance excludes primarily equity-based compensation expense of approximately $0.21-$0.23 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.13 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects |
| • | GAAP diluted EPS guidance does not include the impact of future restructuring charges |
Full Year Fiscal 2025 Outlook
| FY 2025 - Year-over -Year growth | ||||
| Current guidance | Previous guidance | |||
| Revenue Growth, as reported |
(10.9)%-(9.1)% | (11.6)%-(8.4)% | ||
| Revenue Growth, Pro-forma (1) constant currency (2) |
1.7%-3.7% | 1%-4.5% | ||
| GAAP Diluted earnings per share |
28.0%-35.0% | 27.0%-34.0% | ||
| Non-GAAP Diluted earnings per share |
6.5%-10.5% | 6.5%-10.5% | ||
| FY 2025, in millions | ||||||||
| Current guidance | Previous guidance | |||||||
| Free Cash Flow (4) |
$ | 710-$730 | $ | 710-$730 | ||||
| • | Revenue growth on a pro forma(1), constant currency(2) basis adjusts fiscal 2024 revenue by approximately $600 million to reflect the end of several low-margin, non-core business activities, including certain low-margin software and hardware partner activities, Vubiquity’s transactional video on demand business and non-core subscription services; these activities substantially already ceased in the first quarter of fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook |
| • | Full year fiscal 2025 revenue guidance incorporates an expected negative impact from foreign currency fluctuations of approximately 0.5% year-over-year, as compared with a negative impact of approximately 0.6% year-over-year previously, and includes some inorganic contribution |
| • | Non-GAAP diluted earnings per share growth excludes primarily equity-based compensation expense of approximately $0.84-$0.88 per share, amortization of purchased intangible assets and other acquisition-related costs of approximately $0.47 per share, changes in certain acquisitions related liabilities measured at fair value, and other, net of related tax effects |
| • | The impact of the acquisitions on Amdocs’ non-GAAP diluted earnings per share is expected to be immaterial in the full fiscal year 2025 |
| • | GAAP diluted EPS guidance does not include the impact of future restructuring charges |
| • | Non-GAAP operating margin is anticipated to be within a range of 21.1% to 21.7% for the full year fiscal 2025 |
| • | Non-GAAP operating margin is comprised of GAAP operating margin, excluding amortization on purchased intangible assets and other, equity-based compensation expense, restructuring charges, and changes in certain acquisitions related liabilities measured at fair value |
| • | Non-GAAP effective tax rate is anticipated to be within a range of 15% to 17% for the full year fiscal 2025 |
| • | Free cash flow(4) is comprised of cash flow from operations, less net capital expenditures, and excludes payments related to restructuring charges |
The forward-looking statements regarding our third fiscal quarter 2025 and full year fiscal 2025 guidance take into consideration the Company’s current expectations regarding macro and industry specific risks and various uncertainties and certain assumptions that we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, changes to trade policies including tariffs and trade restrictions and the resulting impact on economic activities (as our outlook assumes current economic conditions do not deteriorate significantly due to trade policy or other macro factors), global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities.
Appointment of Board Member
Amdocs is pleased to announce the appointment of Véronique Morali to the Company’s board of directors, effective May 5, 2025, and subject to re-election at Amdocs’ next annual general meeting on Friday, January 30, 2026. For more information, please visit the Investor Relations section of Amdocs’ website at https://investors.amdocs.com/board-directors.
Conference Call and Earnings Webcast Presentation Details
Amdocs will host a conference call and earnings webcast presentation on May 7, 2025 at 5:00 p.m. Eastern Time to discuss the Company’s second quarter of fiscal 2025 results. To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at https://investors.amdocs.com. Presentation slides will be available shortly before the webcast.
Non-GAAP Financial Measures
This release includes non-GAAP diluted earnings per share and other non-GAAP financial measures, including free cash flow, revenue on a constant currency(2) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth. These other non-GAAP measures exclude the following items:
| • | amortization of purchased intangible assets and other acquisition-related costs; |
| • | changes in certain acquisition-related liabilities measured at fair value; |
| • | restructuring and unusual charges or benefits; |
| • | equity-based compensation expense; |
| • | other; and |
| • | tax effects related to the above. |
Free cash flow equals cash generated by operating activities less net capital expenditures. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs’ results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs’ results of operations in conjunction with the corresponding GAAP measures.
Amdocs believes that the presentation of non-GAAP diluted earnings per share and other financial measures, including free cash flow(4), revenue on a constant currency(2) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business.
For its internal budgeting process and in monitoring the results of the business, Amdocs’ management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs’ management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items.
Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below.
Supporting Resources
| • | Keep up with Amdocs news by visiting the Company’s website |
| • | Subscribe to Amdocs’ RSS Feed and follow us on Twitter, Facebook, LinkedIn and YouTube |
About Amdocs
Amdocs helps those who build the future to make it amazing. With our market-leading portfolio of software products and services, we unlock our customers’ innovative potential, empowering them to provide next-generation communication and media experiences for both the individual end user and large enterprise customers. Our employees around the globe are here to accelerate service providers’ migration to the cloud, enable them to differentiate in the 5G era, and digitalize and automate their operations. Listed on the NASDAQ Global Select Market, Amdocs had revenue of $5.00 billion in fiscal 2024.
For more information, visit Amdocs at www.amdocs.com.
This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company’s customers’ businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company’s customers. Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company’s products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company’s offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs’ filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2024, filed on December 17, 2024, and our Form 6-K furnished for the first quarter of fiscal 2025 on February 18, 2025.
Contact:
Matthew Smith
Head of Investor Relations
Amdocs
314-212-8328
E-mail: dox_info@amdocs.com
AMDOCS LIMITED
Consolidated Statements of Income
(In thousands, except per share data)
| Three months ended March 31, |
Six months ended March 31, |
|||||||||||||||
| 2025(a) | 2024 | 2025(a) | 2024 | |||||||||||||
| Revenue |
$ | 1,128,203 | $ | 1,245,849 | $ | 2,238,258 | $ | 2,491,048 | ||||||||
| Operating expenses: |
||||||||||||||||
| Cost of revenue |
698,049 | 801,996 | 1,380,308 | 1,614,740 | ||||||||||||
| Research and development |
81,796 | 91,154 | 166,129 | 180,361 | ||||||||||||
| Selling, general and administrative |
134,625 | 147,609 | 256,712 | 290,113 | ||||||||||||
| Amortization of purchased intangible assets and other |
15,998 | 16,198 | 31,757 | 32,608 | ||||||||||||
| Restructuring charges |
— | 33,160 | 6,783 | 33,160 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| 930,468 | 1,090,117 | 1,841,689 | 2,150,982 | |||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Operating income |
197,735 | 155,732 | 396,569 | 340,066 | ||||||||||||
| Interest and other expense, net |
(8,465 | ) | (11,650 | ) | (14,874 | ) | (21,428 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income before income taxes |
189,270 | 144,082 | 381,695 | 318,638 | ||||||||||||
| Income taxes |
25,269 | 24,657 | 65,842 | 50,491 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income |
$ | 164,001 | $ | 119,425 | $ | 315,853 | $ | 268,147 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income attributable to noncontrolling interests |
758 | 923 | 1,477 | 1,680 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income attributable to Amdocs Limited |
$ | 163,243 | $ | 118,502 | $ | 314,376 | $ | 266,467 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic earnings per share attributable to Amdocs Limited |
$ | 1.46 | $ | 1.02 | $ | 2.80 | $ | 2.28 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted earnings per share attributable to Amdocs Limited |
$ | 1.45 | $ | 1.01 | $ | 2.78 | $ | 2.27 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Cash dividends declared per ordinary share |
$ | 0.527 | $ | 0.479 | $ | 1.006 | $ | 0.914 | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Basic weighted average number of shares outstanding |
111,961 | 116,404 | 112,357 | 116,623 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted weighted average number of shares outstanding |
112,514 | 117,125 | 112,981 | 117,331 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
AMDOCS LIMITED
Selected Financial Metrics
(In thousands, except per share data)
| Three months ended March 31, |
Six months ended March 31, |
|||||||||||||||
| 2025(a) | 2024 | 2025(a) | 2024 | |||||||||||||
| Revenue |
$ | 1,128,203 | $ | 1,245,849 | $ | 2,238,258 | $ | 2,491,048 | ||||||||
| Non-GAAP operating income |
240,106 | 229,434 | 475,504 | 454,675 | ||||||||||||
| Non-GAAP net income |
201,017 | 183,620 | 389,894 | 367,453 | ||||||||||||
| Non-GAAP net income attributable to Amdocs Limited |
200,259 | 182,697 | 388,417 | 365,773 | ||||||||||||
| Non-GAAP diluted earnings per share |
$ | 1.78 | $ | 1.56 | $ | 3.44 | $ | 3.12 | ||||||||
| Diluted weighted average number of shares outstanding |
112,514 | 117,125 | 112,981 | 117,331 | ||||||||||||
Free Cash Flows
(In thousands)
| Three months ended March 31, |
Six months ended March 31, |
|||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net Cash Provided by Operating Activities |
$ | 172,458 | $ | 132,657 | $ | 278,013 | $ | 315,044 | ||||||||
| Purchases of property and equipment, net (b) |
(15,964 | ) | (19,603 | ) | (43,319 | ) | (63,346 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Free Cash Flow |
$ | 156,494 | $ | 113,054 | $ | 234,694 | $ | 251,698 | ||||||||
| (a) | During the three months ended December 31, 2024, we phased out several low-margin, non-core business activities, which were included in the prior periods numbers. |
| (b) | The amounts under “Purchase of property and equipment, net”, include immaterial proceeds from sale of property and equipment for the three and six months ended March 31, 2025 and 2024, respectively. |
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
| Three Months Ended March 31, 2025(a) | ||||||||||||||||||||||||||||||||
| GAAP | Amortization of purchased intangible assets and other |
Equity based compensation expense |
Changes in certain acquisitions related liabilities measured at fair value |
Restructuring charges |
Other | Tax effect |
Non-GAAP | |||||||||||||||||||||||||
| Operating expenses: |
||||||||||||||||||||||||||||||||
| Cost of revenue |
$ | 698,049 | $ | — | $ | (12,356 | ) | $ | (360 | ) | $ | — | $ | — | $ | — | $ | 685,333 | ||||||||||||||
| Research and development |
81,796 | (2,283 | ) | 79,513 | ||||||||||||||||||||||||||||
| Selling, general and administrative |
134,625 | (11,014 | ) | (360 | ) | 123,251 | ||||||||||||||||||||||||||
| Amortization of purchased intangible assets and other |
15,998 | (15,998 | ) | — | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Total operating expenses |
930,468 | (15,998 | ) | (25,653 | ) | (720 | ) | — | — | — | 888,097 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Operating income |
197,735 | 15,998 | 25,653 | 720 | — | — | — | 240,106 | ||||||||||||||||||||||||
| Interest and other expense, net |
(8,465 | ) | (69 | ) | (8,534 | ) | ||||||||||||||||||||||||||
| Income taxes |
25,269 | 5,286 | 30,555 | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income |
164,001 | 15,998 | 25,653 | 720 | — | (69 | ) | (5,286 | ) | 201,017 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income attributable to noncontrolling interests |
758 | 758 | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income attributable to Amdocs Limited |
$ | 163,243 | $ | 15,998 | $ | 25,653 | $ | 720 | $ | — | $ | (69 | ) | $ | (5,286 | ) | $ | 200,259 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Three Months Ended March 31, 2024 | ||||||||||||||||||||||||||||||||
| GAAP | Amortization of purchased intangible assets and other |
Equity based compensation expense |
Changes in certain acquisitions related liabilities measured at fair value |
Restructuring charges |
Other | Tax effect |
Non-GAAP | |||||||||||||||||||||||||
| Operating expenses: |
||||||||||||||||||||||||||||||||
| Cost of revenue |
$ | 801,996 | $ | — | $ | (13,248 | ) | $ | 2,001 | $ | — | $ | — | $ | — | $ | 790,749 | |||||||||||||||
| Research and development |
91,154 | (2,256 | ) | 88,898 | ||||||||||||||||||||||||||||
| Selling, general and administrative |
147,609 | (10,841 | ) | 136,768 | ||||||||||||||||||||||||||||
| Amortization of purchased intangible assets and other |
16,198 | (16,198 | ) | — | ||||||||||||||||||||||||||||
| Restructuring charges |
33,160 | (33,160 | ) | — | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Total operating expenses |
1,090,117 | (16,198 | ) | (26,345 | ) | 2,001 | (33,160 | ) | — | — | 1,016,415 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Operating income |
155,732 | 16,198 | 26,345 | (2,001 | ) | 33,160 | — | — | 229,434 | |||||||||||||||||||||||
| Interest and other expense, net |
(11,650 | ) | 4,004 | (7,646 | ) | |||||||||||||||||||||||||||
| Income taxes |
24,657 | 13,511 | 38,168 | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income |
119,425 | 16,198 | 26,345 | (2,001 | ) | 33,160 | 4,004 | (13,511 | ) | 183,620 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income attributable to noncontrolling interests |
923 | 923 | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income attributable to Amdocs Limited |
$ | 118,502 | $ | 16,198 | $ | 26,345 | $ | (2,001 | ) | $ | 33,160 | $ | 4,004 | $ | (13,511 | ) | $ | 182,697 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
AMDOCS LIMITED
Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP
(In thousands)
| Six Months Ended March 31, 2025(a) | ||||||||||||||||||||||||||||||||
| GAAP | Amortization of purchased intangible assets and other |
Equity based compensation expense |
Changes in certain acquisitions related liabilities measured at fair value |
Restructuring charges |
Other | Tax effect |
Non-GAAP | |||||||||||||||||||||||||
| Operating expenses: |
||||||||||||||||||||||||||||||||
| Cost of revenue |
$ | 1,380,308 | $ | — | $ | (25,606 | ) | $ | (360 | ) | $ | — | $ | — | $ | — | $ | 1,354,342 | ||||||||||||||
| Research and development |
166,129 | (4,554 | ) | 161,575 | ||||||||||||||||||||||||||||
| Selling, general and administrative |
256,712 | (22,013 | ) | 12,138 | 246,837 | |||||||||||||||||||||||||||
| Amortization of purchased intangible assets and other |
31,757 | (31,757 | ) | — | ||||||||||||||||||||||||||||
| Restructuring charges |
6,783 | (6,783 | ) | — | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Total operating expenses |
1,841,689 | (31,757 | ) | (52,173 | ) | 11,778 | (6,783 | ) | — | 1,762,754 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Operating income |
396,569 | 31,757 | 52,173 | (11,778 | ) | 6,783 | — | 475,504 | ||||||||||||||||||||||||
| Interest and other expense, net |
(14,874 | ) | 5,979 | (8,895 | ) | |||||||||||||||||||||||||||
| Income taxes |
65,842 | 10,873 | 76,715 | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income |
315,853 | 31,757 | 52,173 | (11,778 | ) | 6,783 | 5,979 | (10,873 | ) | 389,894 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income attributable to noncontrolling interests |
1,477 | 1,477 | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income attributable to Amdocs Limited |
$ | 314,376 | $ | 31,757 | $ | 52,173 | $ | (11,778 | ) | $ | 6,783 | $ | 5,979 | $ | (10,873 | ) | $ | 388,417 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Six Months Ended March 31, 2024 | ||||||||||||||||||||||||||||||||
| GAAP | Amortization of purchased intangible assets and other |
Equity based compensation expense |
Changes in certain acquisitions related liabilities measured at fair value |
Restructuring charges |
Other | Tax effect |
Non-GAAP | |||||||||||||||||||||||||
| Operating expenses: |
||||||||||||||||||||||||||||||||
| Cost of revenue |
$ | 1,614,740 | $ | — | $ | (26,775 | ) | $ | 3,584 | $ | — | $ | — | $ | — | $ | 1,591,549 | |||||||||||||||
| Research and development |
180,361 | (4,123 | ) | 176,238 | ||||||||||||||||||||||||||||
| Selling, general and administrative |
290,113 | (21,527 | ) | 268,586 | ||||||||||||||||||||||||||||
| Amortization of purchased intangible assets and other |
32,608 | (32,608 | ) | — | ||||||||||||||||||||||||||||
| Restructuring charges |
33,160 | (33,160 | ) | — | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Total operating expenses |
2,150,982 | (32,608 | ) | (52,425 | ) | 3,584 | (33,160 | ) | — | 2,036,373 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Operating income |
340,066 | 32,608 | 52,425 | (3,584 | ) | 33,160 | — | 454,675 | ||||||||||||||||||||||||
| Interest and other expense, net |
(21,428 | ) | 5,538 | (15,890 | ) | |||||||||||||||||||||||||||
| Income taxes |
50,491 | 20,841 | 71,332 | |||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income |
268,147 | 32,608 | 52,425 | (3,584 | ) | 33,160 | 5,538 | (20,841 | ) | 367,453 | ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income attributable to noncontrolling interests |
1,680 | 1,680 | ||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
| Net income attributable to Amdocs Limited |
$ | 266,467 | $ | 32,608 | $ | 52,425 | $ | (3,584 | ) | $ | 33,160 | $ | 5,538 | $ | (20,841 | ) | $ | 365,773 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
AMDOCS LIMITED
Condensed Consolidated Balance Sheets
(In thousands)
| As of | ||||||||
| March 31, 2025 |
September 30, 2024 |
|||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 247,390 | $ | 346,085 | ||||
| Short-term interest-bearing investments |
76,358 | 168,242 | ||||||
| Accounts receivable, net, including unbilled |
957,865 | 1,028,357 | ||||||
| Prepaid expenses and other current assets |
279,656 | 228,498 | ||||||
|
|
|
|
|
|||||
| Total current assets |
1,561,269 | 1,771,182 | ||||||
| Property and equipment, net |
726,701 | 755,601 | ||||||
| Lease assets |
148,145 | 149,254 | ||||||
| Goodwill and other intangible assets, net |
3,055,754 | 3,005,637 | ||||||
| Other noncurrent assets |
712,685 | 704,468 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 6,204,554 | $ | 6,386,142 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
| Current liabilities |
||||||||
| Accounts payable, accruals and other |
$ | 1,162,117 | $ | 1,315,679 | ||||
| Lease liabilities |
38,804 | 39,983 | ||||||
| Deferred revenue |
139,640 | 115,247 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
1,340,561 | 1,470,909 | ||||||
| Lease liabilities |
102,338 | 103,462 | ||||||
| Long-term debt, net of unamortized debt issuance costs |
646,593 | 646,291 | ||||||
| Other noncurrent liabilities |
612,836 | 666,303 | ||||||
| Total Amdocs Limited Shareholders’ equity |
3,460,757 | 3,456,976 | ||||||
| Noncontrolling interests |
41,469 | 42,201 | ||||||
|
|
|
|
|
|||||
| Total equity |
3,502,226 | 3,499,177 | ||||||
|
|
|
|
|
|||||
| Total liabilities and equity |
$ | 6,204,554 | $ | 6,386,142 | ||||
|
|
|
|
|
|||||
AMDOCS LIMITED
Consolidated Statements of Cash Flows
(In thousands)
| Six months ended March 31, |
||||||||
| 2025 | 2024 | |||||||
| Cash Flow from Operating Activities: |
||||||||
| Net income |
$ | 315,853 | $ | 268,147 | ||||
| Reconciliation of net income to net cash provided by operating activities: |
||||||||
| Depreciation, amortization and impairment |
92,822 | 97,851 | ||||||
| Amortization of debt issuance cost |
300 | 296 | ||||||
| Equity-based compensation expense |
52,173 | 52,425 | ||||||
| Deferred income taxes |
2,296 | 559 | ||||||
| Loss from short-term interest-bearing investments |
1,739 | 4,640 | ||||||
| Net changes in operating assets and liabilities, net of amounts acquired: |
||||||||
| Accounts receivable, net |
33,174 | (71,288 | ) | |||||
| Prepaid expenses and other current assets |
(32,526 | ) | 19,305 | |||||
| Other noncurrent assets |
5,141 | (14,493 | ) | |||||
| Lease assets and liabilities, net |
(1,194 | ) | (6,130 | ) | ||||
| Accounts payable, accrued expenses and accrued personnel |
(126,700 | ) | 70,073 | |||||
| Deferred revenue |
27,846 | (48,528 | ) | |||||
| Income taxes payable, net |
(11,082 | ) | (62,228 | ) | ||||
| Other noncurrent liabilities |
(81,829 | ) | 4,415 | |||||
|
|
|
|
|
|||||
| Net cash provided by operating activities |
278,013 | 315,044 | ||||||
|
|
|
|
|
|||||
| Cash Flow from Investing Activities: |
||||||||
| Purchase of property and equipment, net (b) |
(43,319 | ) | (63,346 | ) | ||||
| Proceeds from sale of short-term interest-bearing investments |
92,955 | 31,141 | ||||||
| Purchase of short-term interest-bearing investments |
— | (9,061 | ) | |||||
| Net cash paid for business acquisitions |
(57,169 | ) | (87,129 | ) | ||||
| Net Cash from equity investments and other |
16,741 | (391 | ) | |||||
|
|
|
|
|
|||||
| Net cash provided (used) in investing activities |
9,208 | (128,786 | ) | |||||
|
|
|
|
|
|||||
| Cash Flow from Financing Activities: |
||||||||
| Repurchase of shares |
(279,720 | ) | (273,941 | ) | ||||
| Proceeds from employee stock option exercises |
11,422 | 16,061 | ||||||
| Payments of dividends |
(107,810 | ) | (101,736 | ) | ||||
| Distribution to noncontrolling interests |
(2,209 | ) | (1,744 | ) | ||||
| Payment of contingent consideration and deferred payment of business acquisitions |
(7,599 | ) | (2,063 | ) | ||||
|
|
|
|
|
|||||
| Net cash used in financing activities |
(385,916 | ) | (363,423 | ) | ||||
|
|
|
|
|
|||||
| Net decrease in cash and cash equivalents |
(98,695 | ) | (177,165 | ) | ||||
| Cash and cash equivalents at beginning of period |
346,085 | 520,080 | ||||||
|
|
|
|
|
|||||
| Cash and cash equivalents at end of period |
$ | 247,390 | $ | 342,915 | ||||
|
|
|
|
|
|||||
AMDOCS LIMITED
Supplementary Information
(In millions)
| Three months ended | ||||||||||||||||||||
| March 31, 2025(a) |
December 31, 2024(a) |
September 30, 2024 |
June 30, 2024 |
March 31, 2024 |
||||||||||||||||
| North America |
$ | 738.3 | $ | 737.4 | $ | 835.8 | $ | 828.8 | $ | 823.2 | ||||||||||
| Europe |
180.7 | 155.2 | 184.1 | 175.9 | 184.8 | |||||||||||||||
| Rest of the World |
209.2 | 217.4 | 244.0 | 245.3 | 237.8 | |||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Total Revenue |
$ | 1,128.2 | $ | 1,110.1 | $ | 1,263.9 | $ | 1,250.1 | $ | 1,245.8 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| Three months ended | ||||||||||||||||||||
| March 31, 2025 |
December 31, 2024 |
September 30, 2024 |
June 30, 2024 |
March 31, 2024 |
||||||||||||||||
| Managed Services Revenue |
$ | 747.1 | $ | 728.9 | $ | 721.4 | $ | 740.8 | $ | 720.3 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| as of | ||||||||||||||||||||
| March 31, 2025 |
December 31, 2024 |
September 30, 2024(c) |
June 30, 2024 |
March 31, 2024 |
||||||||||||||||
| 12-Month Backlog |
$ | 4,170 | $ | 4,140 | $ | 4,060 | $ | 4,250 | $ | 4,230 | ||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
| (c) | Excluding the phase out of certain business activities in the fourth fiscal quarter of 2024 only. |
# # #
Exhibit 99.2 Amdocs Limited NASDAQ: DOX Fiscal Q2 2025 Earnings Presentation May 7, 2025 Shuky Sheffer President & CEO Tamar Rapaport-Dagim CFO & COO
Disclaimer The information contained herein in this presentation or delivered or to be delivered to you during this presentation does not constitute an offer, expressed or implied, or a recommendation to do any transaction in Amdocs Limited securities or in any securities of its affiliates or subsidiaries. This presentation and the comments made by members of Amdocs management in conjunction with it can be found on the Investor Relations section of our website, and, as always, a copy of today’s prepared remarks will also be posted immediately following the conclusion of this call. This presentation includes information that constitutes forward- looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs’ growth and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks and uncertainties that may cause future results to differ from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company’s customers’ businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company’s customers. Amdocs’ ability to grow in the business markets that it serves, Amdocs’ ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company’s products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company’s offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs’ filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2024 filed on December 17, 2024, and our Form 6-K furnished for the first quarter of fiscal 2025 on February 18, 2025. This presentation includes non-GAAP financial measures, including non-GAAP operating margin, free cash flow, revenue on a constant currency basis, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited, and non-GAAP earnings per share. Free cash flow equals cash generated by operating activities less net capital expenditures. While in prior years Amdocs used normalized free cash flow, a measure of our operating performance, is further adjusted to exclude net capital expenditures related to the new campus development, payments for non-recurring and unusual charges (such as capital gains tax to be paid in relation to the divestiture of OpenMarket), and payments of acquisition related liabilities, Amdocs is no longer reporting normalized free cash flow. Normalized free cash flow is not comparable to free cash flow. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs’ results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs’ results of operations in conjunction with the corresponding GAAP measures. Please refer to the appendix for a reconciliation of these metrics to the most comparable GAAP provision. This presentation also includes pro forma metrics which exclude the financial impact of OpenMarket (divested on December 31, 2020) from fiscal year 2021. Please also review the information contained in Amdocs’ press release dated February 4, 2025 with respect to earnings for fiscal Q1 2025. The press release contains additional information regarding Amdocs’ outlook for fiscal year 2025 and certain non-GAAP metrics and their reconciliations. IIn nf for orm ma at tiion on Se Sec cu ur riit ty y L Le evel vel 0 0 – – P Pu ub blliic c. . © © 20 2025 25 – – P Pr rop opr riie et ta ar ry y & & Con Conf fiid de en nt tiia all IIn nf for orm ma at tiion on of of A Am md doc ocs s 2 2
Earnings call agenda 1 Strategy & business performance update Shuky Sheffer, President & Chief Executive Officer 2 Financial review & outlook Tamar Rapaport-Dagim, Chief Financial Officer & Chief Operating Officer 3 Q&A IIn nf for orm ma at tiion on Se Sec cu ur riit ty y L Le evel vel 0 0 – – P Pu ub blliic c. . © © 20 2025 25 – – P Pr rop opr riie et ta ar ry y & & Con Conf fiid de en nt tiia all IIn nf for orm ma at tiion on of of A Am md doc ocs s 3 3 3
Today’s speakers Shuky Sheffer President & Chief Executive Officer Tamar Rapaport-Dagim Chief Financial Officer & Chief Operating Officer IIn nf for orm ma at tiion on Se Sec cu ur riit ty y L Le evel vel 0 0 – – P Pu ub blliic c. . © © 20 2025 25 – – P Pr rop opr riie et ta ar ry y & & Con Conf fiid de en nt tiia all IIn nf for orm ma at tiion on of of A Am md doc ocs s 4 4 4
Shuky Sheffer President & Chief Executive Officer Strategy and business performance update 5
Good Q2 Financial Results Non-GAAP Revenue (3)(4) (3) Free cash flow (3) operating margin 12-month backlog Non-GAAP EPS $1.13B 21.3% $156M $1.78 $4.17B (1)(2) +290bps YoY +4.0% YoY +3.5% YoY $181M excluding Above (1) restructuring payments pro forma Phase out of non-core, low- Above the midpoint of the guidance range, margin business activities guidance due to a lower-than- Supported by healthy expected non-GAAP Strong pipeline to deal Ongoing initiatives to drive customer cash collections effective tax rate conversion efficiency gains 1. For comparison purposes, pro forma adjusts second quarter fiscal year 2024 revenue by approximately $150 million and fiscal 2024 revenue by approximately $600 million to reflect the end of certain low margin, non- core business activities; these activities substantially already ceased in the first quarter fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook 2. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period 3. Non-GAAP. See reconciliation tables in appendix 4. Free cash flow of $156 million in the second fiscal quarter, comprised of cash flow from operations of $172 million, less $16 million in net capital expenditures, including $25 million of restructuring payments Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 6 6
Q2 Key Highlights Expanding with new and existing Achieving project milestones for many customers in North America of the world’s largest operators Strengthened relationship: Progressing AT&T mainframe-to-cloud Payment solutions, dealer commissions migration using Amdocs’ agentic paradigm and expanded IT services Delivered an advanced cloud-native platform Japan to modernize and migrate IT systems to cloud connectX SaaS solution Record quarter in managed services Continued sales momentum in cloud Close to managed services 100% contract renewals Leading Tier-1 Cloud migration, partnering with European operator Microsoft Of total revenue ~66% Extended and expanded End-to-end cloud modernization Philippines long-term agreements project Norway Philippines Singapore IIn nf for orm ma at tiion on Se Sec cu ur riit ty y L Le evel vel 0 0 – – P Pu ub blliic c. . © © 20 2025 25 – – P Pr rop opr riie et ta ar ry y & & Con Conf fiid de en nt tiia all IIn nf for orm ma at tiion on of of A Am md doc ocs s 7 7
Strategic Growth Framework Designed to provide the market-leading innovation our customers need Accelerate the journey to the cloud Digitally transform the customer experience for consumer and B2B Monetize the future market potential of next-generation networks Deliver dynamic connected experiences by streamlining and automating complex network ecosystems Simplify and accelerate the adoption of Generative AI IIn nf for orm ma at tiion on Se Sec cu ur riit ty y L Le evel vel 0 0 – – P Pu ub blliic c. . © © 20 202 255 – – P Pr rop opr riie et ta ar ry y & & Con Conf fiid de en nt tiia all IIn nf for orm ma at tiion on of of A Am md doc ocs s 8 8 8
Progress in Strategic Domains - Cloud Strong Accelerate the journey to the cloud Cloud partnerships Selected examples Business value Leading Tier-1 European CSP Enhance performance, accelerate innovation, and Modernization and migration of Amdocs and improve operational efficiency across its markets non-Amdocs applications to the Microsoft Azure cloud Scalable, high-performance Selected for data platforms and additional core cloud infrastructure systems upgrade and migration to AWS in next Philippines phase of cloud modernization project Faster time-to market for new services, greater Consolidate service order management Australia business agility, and improved customer satisfaction solutions to a single cloud platform Our market leadership, strong offering and rich pipeline supports another year of double-digit cloud growth in FY2025 IIn nf for orm ma at tiion on Se Sec cu ur riit ty y L Le evel vel 0 0 – – P Pu ub blliic c. . © © 20 2025 25 – – P Pr rop opr riie et ta ar ry y & & Con Conf fiid de en nt tiia all IIn nf for orm ma at tiion on of of A Am md doc ocs s 9 9
Progress in Strategic Domains – Digital Modernization Digital Digitally transform the customer experience for consumer and B2B modernization Selected examples Business value Quick launch of new digital brands Cloud-native connectX SaaS platform and services One-stop shop for digital subscriptions MarketONE extension and providing an aggregated and convenient expansion of capabilities experience for end users Delivering innovative eSIM technology to millions eSIM go live Mexico of Telcel users Growing list of Strong traction in our Nigeria US customers SaaS next-gen platforms (selected) South Africa Brazil IIn nf for orm ma at tiion on Se Sec cu ur riit ty y L Le evel vel 0 0 – – P Pu ub blliic c. . © © 20 2025 25 – – P Pr rop opr riie et ta ar ry y & & Con Conf fiid de en nt tiia all IIn nf for orm ma at tiion on of of A Am md doc ocs s 10 Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 10
Progress in Strategic Domains - Monetization of Next Generation Networks Monetization of Next Monetize the future market potential of next-generation networks Generation Networks Selected examples Business value Reduce billing processing times by more than Convergent charging modernization half and make customer-facing interactions Bulgaria almost twice as fast Enhanced customer’s billing experience with Bill Experience personalized bill design Current prepaid platform enhancement BSS modernization El Salvador Convergent charging and Unified platform to streamline operations, reduce billing platform modernization complexity and improve customer experience Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 11 Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 11
Progress in Strategic Domains - Network Automation Network Deliver dynamic connected experiences by streamlining and automating complex network ecosystems automation Selected examples Business value Customer Engagement Platform integrated to Modernizing end-to-end customer journeys and Philippines Amdocs’ Intelligent Networking Suite redefining next-generation customer experiences Allowing effective service monetization and Network policy platform for multiple expansion into new markets consumer lines of business Brazil Enabling agility and faster time-to-market with Multi-year extension of OSS engagement Costa Rica assured service quality Positioned to meet strong demand for fiber deployment, orchestration, and digital infrastructure management as global service providers accelerate fiber expansion investments to launch converged, broadband and mobile service offerings Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 12
Amdocs and NVIDIA: Transforming the future of AI in telecom Amdocs recognized at NVIDIA GTC as a key partner driving the next wave of AI innovation in telecom Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 13 13
Progress in Strategic Domains – GenAI A leading enabler of generative AI for the Generative AI world’s leading service providers Strategy Acceleration Product & portfolio evolution Commercial momentum Evolving our data foundation PoCs with several flagship customers capabilities to accelerate GenAI producing highly compelling results adoption including strategy, Data & AI architecture, analytics and more Continued pipeline expansion Network deployment & network operations agents Launched Data and AI ‘foundation’ work AI-powered tools for network design, new network enabling GenAI adoption rollout, and self-healing; built on AI agents Amdocs OSS, NVIDIA, and AWS Powers AI demand monetization - Supporting Tier-1 Canadian operator in their data GPUaaS, LLMs, and vertical apps and AI strategy Launched Amdocs AI Powered by amAIz, Monetization Factory Suite, NVIDIA, and Dell Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 14
Current Operating Environment Macroeconomic uncertainty has risen, but As a specialist software and services provider we believe Amdocs is relatively well to the global communications and media positioned to navigate the present industry, we believe Amdocs is not currently environment due to our unique business directly affected by the announced tariffs model Working hard to convert new deals, leveraging technology leadership, project Rich and encouraging pipeline of and operations expertise, and a proven opportunities across a serviceable ability to support industry consolidation addressable market of nearly $60 billion We believe Amdocs is relatively well positioned to manage near-term uncertainty while monitoring for any indirect impacts on us and our customers’ spending behavior Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 15 15
FY 2025 Outlook: On-track to Deliver Expected Double- Digital Total Shareholder Returns for the 5th Year Running A B 1.7%-3.7% YoY growth $710m-$730m Reiterating 2.7% midpoint in pro forma, Free cash (1)(2) >90% earning-to-cash flow Revenue constant currency, while tightening the range flow conversion, and attractive Double-digit cloud growth in FY2025 (4)(5) free cash flow yield of ~7% C D 21.1% - 21.7% 6.5%-10.5% % margin YoY growth Non-GAAP Non-GAAP (3) Tracking towards the guidance midpoint, (3) EPS EBIT Positioned for double-digit up 300 bps from a year ago including expected total shareholder 60-70 bps from internal efficiency gains (6) returns in FY2025 1. For comparison purposes, pro forma adjusts second quarter fiscal year 2024 revenue by 3. Non-GAAP. See reconciliation tables in appendix approximately $150 million and fiscal 2024 revenue by approximately $600 million to 4. Yield = expected free cash flow of $720M, the midpoint of FY2025 FCF guidance, as a percentage of Amdocs’ market reflect the end of certain low margin, non-core business activities; these activities capitalization as of 5/7/2025 substantially already ceased in the first quarter fiscal 2025 and are not included in the 5. FY2025 excludes restructuring payments full year fiscal 2025 revenue outlook 6. Expected total shareholder return = Non-GAAP EPS growth plus dividend yield); FY2025E assumed midpoint of pro forma non-GAAP 2. Constant currency. Assumes exchange rates in the current period were unchanged EPS outlook, and dividend yield based on quarterly rate of $0.527 as of share price on 11/12/24 from the prior period Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 16
Tamar Rapaport-Dagim Chief Financial Officer & Chief Operating Officer Financial review & outlook 17
Q2 2025 Revenue vs. Guidance Q2 2025 Results $ Millions Q2 FY2025 Q2 Revenue Financial Highlights $1,128 million $1,128 $1,125 Above guidance midpoint despite ~$2M negative currency impact Revenue, -9.4% YoY as reported, ($1,105M - $1,145M) reflecting phase-out of certain business activities Original Q2F25 Q2F25A (1) Revenue +4.0% YoY in pro forma (3) Guidance (midpoint) Q2 Non-GAAP Operating Margin (2) constant currency 21.3%, +290bps YoY Q2 revenue above the guidance +10 bps QoQ midpoint, despite currency headwinds Q2 2025 Revenue by Region $ Millions Significantly improved operating profitability Rest of World Q2 GAAP Diluted EPS reflecting phase out of low margin business ~$209 $1.45 above the guidance range activities and ongoing efficiency gains ~19% ($1.30 - $1.38) North 1. For comparison purposes, pro forma adjusts first quarter fiscal year 2024 revenue America by approximately $150 million and fiscal 2024 revenue by approximately $600 ~$738 ~16% Europe million to reflect the end of certain low margin, non-core business activities; these ~65% activities substantially already ceased in the first quarter fiscal 2025 and are not ~$181 (3) included in the full year fiscal 2025 revenue outlook Q2 Non-GAAP Diluted EPS 2. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period $1.78 above the guidance range 3. Non-GAAP. See reconciliation tables in appendix ($1.67 - $1.73) Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 18 18 Information of Amdocs
Managed Services Revenue: Q2 2025 Visibility & Business $ Millions Resiliency: 66% of Q2 2025 revenue Managed services $747 Managed Services arrangements support $720 business model resiliency with highly recurring revenue streams, multi- year engagements and Record Managed Services high renewal rates, and may also include large- scale digital ~$747M transformation projects ~66% of total revenue in Q2 2025 Q2F24 Q2F25 Multi-year managed services extension to manage M1’s new cloud-native charging platform Close to managed services Expanded managed services engagement to cover non-Amdocs contract renewals ~100% applications Extended long-term strategic relationship through 2030 to deliver enhanced managed services Norway Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 19 19 Information of Amdocs
(1) DSO’s Q2 2025 Free cash flow bridge Balance Sheet 77 days FCF includes ~$25M restructuring payments* +1 days YoY and -4 days QoQ & Cash Flow DSO’s may fluctuate from quarter to quarter * ~$181 ~$16 ~$172 Unbilled receivables net of deferred revenue declined by $25 million sequentially in Q2, aggregating the short- $156 term and long-term balances (1) Q2 2025 free cash flow of $181 The net difference between unbilled receivables and million before ~$25 million of deferred revenue fluctuates from quarter to quarter, in line with normal business activities as well as progress restructuring payments on significant multi-year transformation programs we Operating Cash Net capex Reported FCF are currently running in North America. Flow *Figures may not sum due to rounding Ample liquidity to support ongoing business needs while retaining the Cash, Credit Facility & Debt Position capacity to fund future strategic $ Millions, as of March 31, 2025 Liquidity: Cash + Credit Facility growth investments $824 million Credit Ample liquidity including available Facility $500 $500M revolving credit facility $650 Cash Baa1 BBB Moody’s S&P ~$324 1. Non-GAAP. See reconciliation tables in appendix 2. $650M senior note, maturing June 2030 (2) Committed to maintaining our Liquidity Debt Investment grade credit rating Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 20 20 Information of Amdocs
Q2 2025 Cash Returned to Shareholders Dividend Disciplined Capital $ Millions Board authorized quarterly dividend payment: 52.7 cents Payable on July 25, 2025, Allocation Dividends, to shareholders on record date of June 30, 2025 $54 Share Repurchase Authorization (1) Reiterating FY 2025 free cash flow (FCF) Share ~$1.26B aggregate remaining share repurchases, of between $710-$730M before repurchase authorization, including $258M existing $135 $189M share repurchase capacity as of March 31, 2025, restructuring payments, equating to >90% and a new authorization of $1B approved by cash conversion Returned to shareholders in Q2 board of directors, with no expiration date (2) ~7% free cash flow yield FCF: Five-year historical trend and FY2025E outlook (1)(3)(4)(5)(6)(7) 140% Expects to return the majority of free 102% 101% >90% (1)(3)(5)(6)(7) 93% 88% % FCF / cash flow to shareholders in FY2025 (1) Non-GAAP Net Income FY2025E 112% 104% 100% 99% guidance: 96% (1)(3)(5)(6)(7) % of FCF Returned 1. Non-GAAP. See appendix tables for reconciliation of FCF return 2. Yield = expected free cash flow of $720M, the mid point of FY2025 FCF guidance to Shareholders before restructuring payments, as a percentage of Amdocs’ market majority capitalization as of 5/7/2025 3. FCF in FY2020, FY2021 and FY2022 is presented on a normalized basis, which mainly excludes net capital expenditures related to the new campus $869 development; normalized FCF disclosure is not applicable as of FY2023 onward $718 $720 $694 $665 (1)(3)(5)(6)(7) 4. Refer to https://investors.amdocs.com/ and earnings reports issued on 11/2/2021 FCF ($M) $527 and 11/8/2022 for reconciliation of normalized FCF in FY2020, FY2021 and FY2022 5. FY2023 excludes $20M restructuring payments 6. FY2024 excludes $75M restructuring payments FY2020 FY2021 FY2022 FY2023 FY2024 FY2025E 7. FY2025 assumes midpoint of $710-$730M guidance range, before restructuring payments (Guidance) (1)(3) Normalized Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 21 21 Information of Amdocs
Quarterly 12-Month Backlog Growth YoY % Leading Indicators 3.5% & Visibility: 2.9% 2.9% 12-Month Backlog as of 2.7% 2.7% 2.5% March 31, 2025 12-Month Backlog $4.17B Up 3.5% 12-month backlog up 3.5% on a pro (1) (1) YoY on a pro-forma , (1) (1) forma basis (1) basis Q1F24 Q2F24 Q3F24 Q4F24 Q1F25 Q2F25 12-month backlog increased by +$30M QoQ in Q2 FY2025 Leading Indicator 12-month backlog includes: Anticipated revenue related to contracts Estimated revenue from managed services contracts ~90% 1. For comparison purposes, pro forma adjusts first quarter fiscal year 2024 revenue by approximately $150 million and fiscal 2024 revenue by Letters of intent approximately $600 million to reflect the end of certain low margin, non- core business activities; these activities substantially already ceased in 12-month backlog as Maintenance the first quarter fiscal 2025 and are not included in the full year fiscal percent of forward 2025 revenue outlook 12-month revenue Estimated ongoing support activities Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 22 22 Information of Amdocs
FY2025 Revenue Growth Revenue (3) YoY% Growth Constant Currency Growth Outlook 10.3% Reiterating the 2.7% midpoint of 7.7% FY2025 revenue growth outlook of 7.0% (1) 1.7%-3.7% YoY in pro forma constant (3) currency Reiterating 3.7% Cloud on-track for another year of 2.7% 2.7% 2.4% double-digit growth in FY2025E guidance midpoint 1.7% (2)(3) (3) (3) (3) (3) (1) (2)(3) FY2020 FY2021 FY2022 FY2023 FY2024 FY2025E 1. For comparison purposes, pro forma adjusts first quarter fiscal year 2024 revenue by approximately $150 million and fiscal 2024 revenue by approximately $600 million to reflect the end of certain low margin, non- core business activities; these activities substantially already ceased in the first quarter fiscal 2025 and are not included in the full year fiscal 2025 revenue outlook 2. Pro forma metrics exclude the financial impact of OpenMarket (which was divested on December 31, 2020) from fiscal year 2021. 3. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 23 23 Information of Amdocs
(1) Enhanced Annual Non-GAAP Operating Margin: (2) FY2018 – FY2025E Profitability $ Millions Improvement FY2025E Non-GAAP(1) Operating margin target range: 21.1%-21.7% (1) Reiterating FY2025 non-GAAP 21.7% operating margin guidance of 21.1%- 21.7%, up 300 bps YoY at midpoint 21.1% +300 bps YoY at guidance Phase out of certain business activities midpoint expected to drive roughly 230 bps of improvement 18.4% 18.7% 17.8% 18.1% 17.6% Operational excellence, automation and 17.5% 17.8% 17.3% 17.3% 17.2% 17.5% gradual implementation of Gen AI will 17.2% support about 60-70 bps of margin 16.5% expansion at the guidance midpoint 1. Non-GAAP. See reconciliation tables in appendix 2. Refer to https://investors.amdocs.com/ and earnings reports issued on 11/8/2018, 11/12/19, 11/10/20, 11/2/2021, 11/8/2022, 11/7/2023 and 11/12/2024 for reconciliation of non-GAAP operating margin in FY2018, FY2019, FY2020, FY2021, FY2022, FY2023 and FY2024 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025E Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 24 24 Guidance Range Non-GAAP Operating Margin Information of Amdocs
(3)(4) Total Shareholder Return (2) Targeting double-digit Non-GAAP Diluted EPS Growth YoY % + Dividend Yield (1) FY21 and FY22 non-GAAP EPS growth is presented pro forma expected total (3) shareholder returns for th 5 consecutive year of the 5th year running in double-digit expected total shareholder returns* in FY2025 FY2025E 14.1% 13.6% 11.7% 11.2% (2) 10.8%* Reiterating non-GAAP EPS growth 12.1% 11.5% of 6.5%-10.5% in FY2025E 10.5% Reiterating 9.8% 9.0% 8.5% guidance 5.3% 6.5% midpoint 3.0% 1. Pro forma metrics exclude the financial impact of OpenMarket (which was divested on December 31, 2020) from fiscal year 2021. 2.3% 2.2% 2.1% 2.3% 2. Non-GAAP. See reconciliation tables in appendix 2.0% 1.9% 3. Expected total shareholder return assumes Non-GAAP EPS growth (1) (1) plus dividend yield (based on fiscal year end closing share price); FY2020 FY2021 FY2022 FY2023 FY2024 FY2025E FY2025E assumed 8.5% midpoint of non-GAAP EPS outlook, and dividend yield based on quarterly rate of $0.527 as of share price Non-GAAP Diluted EPS Growth Dividend Yield Total Shareholder Return on 11/12/24 4. Refer to https://investors.amdocs.com/ and earnings reports issued (2) *Non-GAAP EPS growth of 8.5%, plus ~2.3% dividend yield on 11/10/2020, 11/2/2021, 11/8/2022, 11/7/2023 and 11/12/2024 for non-GAAP reconciliation in FY2019, FY2020, FY2021, FY2022, FY2023 and FY2024 Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 25 25 Information of Amdocs
Q&A Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 26 26 26
Appendix Outlook & Reconciliation Tables Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information of Amdocs 27 27 27
Q3 Fiscal 2025 Outlook Q3 & FY2025 Revenue $1,110 - $1,1150 million $1.30 - $1.38 GAAP EPS Outlook (1) Non-GAAP EPS $1.68 - $1.74 Share Count 111 million Positioned to deliver double-digit expected total shareholder returns Full Year Fiscal 2025 Outlook Updated Previous for the fifth year running Revenue growth (10.9)% - (9.1)% (11.6)% - (8.4)% As reported Revenue growth 1.7% - 3.7% 1% - 4.5% (2) (3) Pro forma Constant currency 28.0% - 35.0% 27.0% - 34.0% GAAP EPS growth (1) Non-GAAP EPS growth 6.5% - 10.5% 6.5% - 10.5% Operating Margin 21.1% - 21.7% 21.1% - 21.7% 1. Non-GAAP. See reconciliation tables in appendix. Free cash (1) Non-GAAP flow outlook is before expected restructuring payments 2. For comparison purposes, pro forma adjusts fiscal 2024 Effective Tax Rate 15.0% - 17.0% 15.0% - 17.0% revenue by approximately $600 million to reflect the end of (1) Non-GAAP certain low margin, non-core business activities which substantially already ceased in the first quarter of fiscal 2025 (1) Free cash flow $710-$730 million $710-$730 million and are not included in the full year fiscal 2025 revenue outlook 3. Constant currency. Assumes exchange rates in the current period were unchanged from the prior period Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 28 28 Information of Amdocs
Selected Financial Metrics a) During the three months ended December 31, 2024, we phased out several low-margin, non- core business activities, which were included in the prior periods numbers b) The amounts under Purchase of property and equipment, net”, include immaterial proceeds from sale of property and equipment for the six and three months ended March 31, 2025 and 2024, respectively Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 29 29 Information of Amdocs
Reconciliation Tables Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 30 30 Information of Amdocs
Reconciliation Tables Information Security Level 0 – Public. © 2025 – Proprietary & Confidential Information Security Level 2 – Sensitive. © 2025 – Proprietary & Confidential Information of Amdocs 31 31 Information of Amdocs
Thank YOU